Am­gen is join­ing the bio­phar­ma ex­o­dus out of neu­ro­sciences R&D, cut­ting 180 R&D jobs in re­or­ga­ni­za­tion

Three months af­ter Am­gen fold­ed up a late-stage Alzheimer’s study of their failed BACE in­hibitor part­nered with No­var­tis, the phar­ma gi­ant is join­ing the gen­er­al ex­o­dus out of neu­ro­sciences. And they’re cut­ting some 180 po­si­tions as a re­sult of the re­or­ga­ni­za­tion.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER